Report of the Review Committee on the Functioning of the International Health Regulations (2005) in relation to Pandemic (H1N1) 2009
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
Letter of the holy father
Clinical care for severe acute respiratory infection: toolkit: COVID-19 adaptation
Clinical care for severe acute respiratory infection: toolkit: COVID-19 adaptation
This SOP describes specific step by step procedures in clinical management like OPD, IPD Housekeeping, Emergency services, OT services, Radiology Services & Pathology services. It should be used as a hands-on reference for service providers providing services, thereby helping to standardize the prac...tice in all hospitals, with the ultimate goal of optimizing the quality & standard patient care. The manual may also be used as a reference for health service providers for effective health management.
more
This publication describes the first WHO public-benefit Target Product Profiles (TPPs) for snakebite antivenoms. It focuses on antivenoms for treatment of snakebite envenoming in sub-Saharan Africa. Four TPPs are described in the document:
Broad spectrum Pan-African polyvalent antivenoms: products ...that are intended for widespread utility throughout sub-Saharan Africa for treatment of envenoming irrespective of the species of snake causing a bite. Monovalent antivenoms for specific use cases: for products for a single species (or genus) of snake (e.g., boomslangs or carpet viper antivenoms).
Syndromic Pan-African polyvalent antivenoms for neurotoxic envenoming: products that are intended for treatment of envenoming by species whose venoms are neurotoxic. Syndromic Pan-African polyvalent antivenoms for non-neurotoxic envenoming: products for snakebite envenoming where the effects are largely haemorrhagic, necrotic or procoagulant.
more